What's in Sherief Abd-Elsalam's pipeline?

Sherief Abd-Elsalam has 18 drugs in our index: 5 marketed, 0 filed, 13 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Sherief Abd-Elsalam's portfolio?

Top competitors by shared drug class: National Taiwan University Hospital, Hospices Civils de Lyon, Kaohsiung Medical University Chung-Ho Memorial Hospital, Pfizer, Ahn-Gook Pharmaceuticals Co.,Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sherief-abd-elsalam.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sherief Abd-Elsalam — Portfolio Competitive Intelligence Brief

Sherief Abd-Elsalam pipeline: 5 marketed, 0 filed, 13 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 13 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
FOLFERI	FOLFERI	marketed			Other
Folferi and celecoxib	Folferi and celecoxib	marketed	Chemotherapy combination with COX-2 inhibitor	Topoisomerase I (irinotecan), thymidylate synthase (fluorouracil), COX-2	Oncology
Coenzyme Q	Coenzyme Q	marketed
Quadruple therapy	Quadruple therapy	marketed	Antiviral combination therapy		Virology/Hepatology
Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir	Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir	marketed
CHOP Plus Lanzoprazole	CHOP Plus Lanzoprazole	phase 3	Combination chemotherapy regimen with proton pump inhibitor	H+/K+-ATPase (lansoprazole component); multiple targets (CHOP chemotherapy)	Oncology; Gastroenterology
Folfox with avastin	Folfox with avastin	phase 3	Chemotherapy combination + monoclonal antibody (anti-VEGF)	DNA (chemotherapy); VEGF (bevacizumab)	Oncology
nonselective beta blocker	nonselective beta blocker	phase 3	nonselective beta blocker	beta-adrenergic receptors	Cardiovascular
Pantoprazole low dose	Pantoprazole low dose	phase 3	Proton pump inhibitor (PPI)	H+/K+-ATPase (proton pump)	Gastroenterology
CHOP Plus Famotidine	CHOP Plus Famotidine	phase 3	Combination chemotherapy with gastroprotective agent		Oncology
Nigetella salivata	Nigetella salivata	phase 3
Sofosbuvir and Daklatasuvir	Sofosbuvir and Daklatasuvir	phase 3	NS5B RNA-dependent RNA polymerase inhibitor and NS5A inhibitor	HCV NS5B RNA-dependent RNA polymerase and HCV NS5A protein	Infectious Disease

Therapeutic area mix

Oncology · 4
Gastroenterology · 2
Infectious Disease · 2
Cardiovascular · 2
Other · 2
Oncology; Gastroenterology · 1
Virology/Hepatology · 1
Immunology; Nutritional support · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

National Taiwan University Hospital · 3 shared drug classes
Hospices Civils de Lyon · 2 shared drug classes
Kaohsiung Medical University Chung-Ho Memorial Hospital · 2 shared drug classes
Pfizer · 2 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
Akeso · 1 shared drug class
ATGC Co., Ltd. · 1 shared drug class
Addpharma Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sherief Abd-Elsalam:

Cite this brief

Drug Landscape (2026). Sherief Abd-Elsalam — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sherief-abd-elsalam. Accessed 2026-05-16.